Brief: Bioinvent: Phase 1 Study Part B, I.E. Bt-001 In Combination With Pembrolizumab To Start In H2

BioInvent International AB

30/08/2023 07:12

Aug 30 (Reuters) - BioInvent International AB  BINV.ST :
    * OUTLOOK: PHASE 1 STUDY PART B, I.E. BT-001 IN COMBINATION
WITH 
PEMBROLIZUMAB, IS PLANNED TO START IN H2 2023

Source text for Eikon:  ID:nMFN5g7j5V 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))